ATE476428T1 - Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen - Google Patents
Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomenInfo
- Publication number
- ATE476428T1 ATE476428T1 AT05704874T AT05704874T ATE476428T1 AT E476428 T1 ATE476428 T1 AT E476428T1 AT 05704874 T AT05704874 T AT 05704874T AT 05704874 T AT05704874 T AT 05704874T AT E476428 T1 ATE476428 T1 AT E476428T1
- Authority
- AT
- Austria
- Prior art keywords
- estrogen receptor
- treatment
- vasomotor symptoms
- selective modulators
- symptoms
- Prior art date
Links
- 230000001457 vasomotor Effects 0.000 title abstract 2
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000033830 Hot Flashes Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 206010029410 night sweats Diseases 0.000 abstract 1
- 230000036565 night sweats Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrane Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53844204P | 2004-01-22 | 2004-01-22 | |
| US53834204P | 2004-01-22 | 2004-01-22 | |
| PCT/US2005/000020 WO2005073204A1 (en) | 2004-01-22 | 2005-01-18 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE476428T1 true ATE476428T1 (de) | 2010-08-15 |
Family
ID=34830456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05704874T ATE476428T1 (de) | 2004-01-22 | 2005-01-18 | Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20090023917A1 (de) |
| EP (1) | EP1709021B1 (de) |
| JP (1) | JP4909086B2 (de) |
| KR (2) | KR100849559B1 (de) |
| CN (1) | CN102250042A (de) |
| AT (1) | ATE476428T1 (de) |
| AU (1) | AU2005207821B2 (de) |
| BR (1) | BRPI0506721A (de) |
| CA (1) | CA2551956C (de) |
| CR (1) | CR8517A (de) |
| DE (1) | DE602005022673D1 (de) |
| EA (2) | EA012262B1 (de) |
| EC (1) | ECSP066711A (de) |
| ES (1) | ES2347973T3 (de) |
| IL (1) | IL176738A0 (de) |
| MA (1) | MA28436B1 (de) |
| NO (1) | NO20063760L (de) |
| SG (1) | SG149867A1 (de) |
| UA (1) | UA85862C2 (de) |
| WO (1) | WO2005073204A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| US10144736B2 (en) * | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| US20100087402A1 (en) * | 2008-09-29 | 2010-04-08 | Vivus, Inc. | Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders |
| AU2009296974B2 (en) * | 2008-09-29 | 2013-06-27 | Eli Lilly And Company | Selective estrogen repector modulator for the treatment of osteoarthritis |
| US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| SI2568806T1 (sl) | 2010-05-12 | 2016-09-30 | Radius Health, Inc. | Režimi zdravljenja |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| FR3014437B1 (fr) * | 2013-12-05 | 2016-12-23 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
| FR3014434B1 (fr) * | 2013-12-05 | 2015-12-25 | Servier Lab | Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| EP4035664A3 (de) | 2014-03-28 | 2022-11-30 | Duke University | Behandlung von krebs unter verwendung von selektiven östrogenrezeptormodulatoren |
| PL3097102T3 (pl) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego |
| RU2769527C2 (ru) | 2016-06-22 | 2022-04-01 | Эллипсес Фарма Лтд | Способы лечения ar+ рака молочной железы |
| KR102268448B1 (ko) | 2016-09-02 | 2021-06-22 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| DK3565542T3 (da) | 2017-01-05 | 2024-07-01 | Radius Pharmaceuticals Inc | Polymorphic forms of rad1901-2hcl |
| CN108675999B (zh) * | 2018-05-09 | 2021-03-16 | 浙江农林大学暨阳学院 | 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法 |
| KR102792490B1 (ko) | 2018-07-04 | 2025-04-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| TWI702219B (zh) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| CN112424205B (zh) | 2018-07-12 | 2023-10-31 | 伊莱利利公司 | 选择性的雌激素受体降解剂 |
| MX2021009569A (es) | 2019-02-12 | 2021-09-08 | Radius Pharmaceuticals Inc | Procesos y compuestos. |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| TWI894443B (zh) | 2021-03-16 | 2025-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| US11926634B2 (en) | 2022-02-01 | 2024-03-12 | Eli Lilly And Company | Processes for the preparation of selective estrogen receptor degraders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
| US5726186A (en) * | 1995-09-08 | 1998-03-10 | Eli Lilly And Company | Pentacyclic compounds, intermediates, processes, compositions, and methods |
| CA2213810C (en) * | 1996-08-29 | 2006-06-06 | Lewis Dale Pennington | Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods |
| ID19392A (id) * | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
| US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| CA2217810A1 (en) * | 1996-10-10 | 1998-04-10 | Eli Lilly And Company | 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods |
| AU8683398A (en) * | 1997-08-07 | 1999-03-01 | Eli Lilly And Company | 1-{4-(substituted alkoxy)benzyl}naphthalene compounds having estrogen inhibitoryactivity |
| ATE433322T1 (de) * | 2002-07-22 | 2009-06-15 | Lilly Co Eli | Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten |
-
2005
- 2005-01-18 AT AT05704874T patent/ATE476428T1/de not_active IP Right Cessation
- 2005-01-18 CN CN2011101337521A patent/CN102250042A/zh active Pending
- 2005-01-18 UA UAA200607867A patent/UA85862C2/uk unknown
- 2005-01-18 KR KR1020067014630A patent/KR100849559B1/ko not_active Expired - Fee Related
- 2005-01-18 BR BRPI0506721-9A patent/BRPI0506721A/pt not_active IP Right Cessation
- 2005-01-18 SG SG200900414-4A patent/SG149867A1/en unknown
- 2005-01-18 US US10/597,241 patent/US20090023917A1/en not_active Abandoned
- 2005-01-18 AU AU2005207821A patent/AU2005207821B2/en not_active Ceased
- 2005-01-18 CA CA2551956A patent/CA2551956C/en not_active Expired - Fee Related
- 2005-01-18 EA EA200601353A patent/EA012262B1/ru not_active IP Right Cessation
- 2005-01-18 KR KR1020087003065A patent/KR101008804B1/ko not_active Expired - Fee Related
- 2005-01-18 WO PCT/US2005/000020 patent/WO2005073204A1/en not_active Ceased
- 2005-01-18 EP EP05704874A patent/EP1709021B1/de not_active Expired - Lifetime
- 2005-01-18 DE DE602005022673T patent/DE602005022673D1/de not_active Expired - Lifetime
- 2005-01-18 ES ES05704874T patent/ES2347973T3/es not_active Expired - Lifetime
- 2005-01-18 JP JP2006551097A patent/JP4909086B2/ja not_active Expired - Fee Related
- 2005-01-18 EA EA200900586A patent/EA016613B1/ru not_active IP Right Cessation
-
2006
- 2006-07-06 IL IL176738A patent/IL176738A0/en unknown
- 2006-07-19 EC EC2006006711A patent/ECSP066711A/es unknown
- 2006-07-19 CR CR8517A patent/CR8517A/es unknown
- 2006-08-18 MA MA29277A patent/MA28436B1/fr unknown
- 2006-08-22 NO NO20063760A patent/NO20063760L/no not_active Application Discontinuation
-
2011
- 2011-06-23 US US13/167,343 patent/US8217032B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005207821B2 (en) | 2011-02-10 |
| EP1709021B1 (de) | 2010-08-04 |
| US20110281847A1 (en) | 2011-11-17 |
| US20090023917A1 (en) | 2009-01-22 |
| US8217032B2 (en) | 2012-07-10 |
| JP2007519721A (ja) | 2007-07-19 |
| UA85862C2 (uk) | 2009-03-10 |
| SG149867A1 (en) | 2009-02-27 |
| IL176738A0 (en) | 2006-10-31 |
| EA012262B1 (ru) | 2009-08-28 |
| EA200900586A1 (ru) | 2009-08-28 |
| KR101008804B1 (ko) | 2011-01-14 |
| CR8517A (es) | 2006-12-01 |
| ES2347973T3 (es) | 2010-11-26 |
| NO20063760L (no) | 2006-10-16 |
| AU2005207821A1 (en) | 2005-08-11 |
| EA016613B1 (ru) | 2012-06-29 |
| DE602005022673D1 (de) | 2010-09-16 |
| EP1709021A1 (de) | 2006-10-11 |
| CN102250042A (zh) | 2011-11-23 |
| JP4909086B2 (ja) | 2012-04-04 |
| ECSP066711A (es) | 2006-10-31 |
| BRPI0506721A (pt) | 2007-05-02 |
| CA2551956A1 (en) | 2005-08-11 |
| KR20060129277A (ko) | 2006-12-15 |
| KR100849559B1 (ko) | 2008-07-31 |
| WO2005073204A1 (en) | 2005-08-11 |
| EA200601353A1 (ru) | 2007-02-27 |
| KR20080016755A (ko) | 2008-02-21 |
| MA28436B1 (fr) | 2007-02-01 |
| CA2551956C (en) | 2013-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE476428T1 (de) | Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| EA201101475A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
| SG155188A1 (en) | Pyrrole derivatives as pharmaceutical agents | |
| TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CY1108794T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| MY149855A (en) | Benzimidazole derivatives and their use for modulating the gaba? receptor complex | |
| NO20084792L (no) | Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
| TW200738669A (en) | Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide | |
| DE50109156D1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| ATE555108T1 (de) | Polyamide zur behandlung des menschlichen papilloma-virus | |
| ATE399557T1 (de) | Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen | |
| ATE457027T1 (de) | Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht | |
| CR11447A (es) | Moduladores de piperidinil y piperazinil de y secretasa | |
| ATE392471T1 (de) | Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren | |
| MY157425A (en) | Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | |
| EA201000732A1 (ru) | Производные s-алкилизотиурония для лечения нарушений, обусловленных гиперсократимостью матки | |
| ATE432275T1 (de) | Pyrrol- bzw. imidazolamide zur behandlung von obesitas | |
| WO2008128155A3 (en) | SIRTUIN BASED METHODS AND COMPOSITIONS FOR TREATING β- CATENIN-RELATED CONDITIONS | |
| EA200702604A1 (ru) | Производные бензофуранона как нестероидные модуляторы рецептора прогестерона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |